Login to Your Account



Other News To Note


Wednesday, July 17, 2013
• Advancell SA, of Barcelona, Spain, and Helsinn Healthcare SA, of Lugano, Switzerland, signed a partnering agreement to develop and commercialize ATH008, a topical product designed to prevent and treat palmoplantar erythrodysesthesia syndrome, or PPES, often caused by fluoropyrimidines-based chemotherapy, and hand-foot skin reactions, or HFSR, often caused by multitargeted kinase inhibitors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription